

Mucormycosis in ENT

Avani Mahajan

Choithram Hospital and Research Centre, India



Abstract

Mucormycosis is an opportunistic fulminating fungal infection caused by rhizopus species; frequently in immune compromised patients. 39% of total mucormycosis is in the sinonasal form. Through its angioinvasive property it invades the nasal mucosa, blood vessels, sinuses and spreads intracranially. Presenting here is a case series of 15 patients in period from June 2018- June 2019 with mucormycosis. The clinical stages, detailed evaluation and early diagnosis are the crux of the management of mucor. Surgical debridement with potent antifungal (amphotericin) remains the foundation of the treatment. It is important for the otorhinolaryngologist and head and neck surgeon to be familiar with this aggressive infection, which carries high mortality and morbidity. The appropriate and timely diagnosis and treatment can improve prognosis and patient survival.



Biography

Avani Mahajan. she completed my MBBS in March 2018 at the age of 23, after which I joined post-graduation in DNB ENT in May 2018. Currently I am 2nd year resident at Choithram hospital and research Centre, Indore Madhya Pradesh, India. Doing an ongoing study for my thesis submission (topic- the comparative study of CT scan and diagnostic nasal endoscopy findings of lateral wall of nose in headache of rhinogenic origin). Attended many otolaryngology conferences, workshops and CMEs in all over India.

Publications

1. Battikh R, Labben I, Ben Abdelhafidh N, et al. Mucormycose rhinofaciale : à propos de 3 cas. Med Mal Infect 2003;33:427–30.
2. Trabelsi A, Soua A, Sriha B, et al. Mucormycose et diabète : à propos de troiscas. Rev Med Liege 2005;60:545–8.
3. Charfi S, Ayadi L, Makni S, et al. Mucormycose rhinocérébrale : étude anatomo-clinique de 7 cas. J Mycol Med 2008;18:46–52.
4. Yun MW, Lui CC, Chen WJ. Facial paralysis secondary to tympanic mucormycosis: case report. Am J Otol 1994;15:413–4.
5. Almannai M, Imran H, Estrada B, Siddiqui AH. Successful treatment of rhino-orbital mucormycosis with posaconazole and hyperbaric oxygen therapy. Pediatr Hematol Oncol 2013;30:184–6

[10th World Congress on Otolaryngology](#) | June 22-23, 2020

Citation: Avani Mahajan, Mucormycosis in ENT, Otolaryngology 2020, 10th World Congress on Otolaryngology, June 22-23, 2020, PP. 5